Literature DB >> 3122741

The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin.

D M Robertson1, R Klein, F L de Vos, R I McLachlan, R E Wettenhall, M T Hearn, H G Burger, D M de Kretser.   

Abstract

Three proteins (31, 35 and 39 kDa) with inhibin-like activity have been isolated from bovine follicular fluid with identical NH2-terminal amino acid sequences. These polypeptides are distinct from inhibin, based on their different NH2-amino acid sequence, molecular masses, absence of a subunit structure, absence of inhibin immunoactivity and the failure of inhibin antiserum to neutralize their bioactivity in vitro. Their inhibin-like biological activities based on their ability to suppress FSH cell content by pituitary cells in culture are 5-10% of bovine 31 kDa inhibin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122741     DOI: 10.1016/0006-291x(87)90430-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

Review 1.  Recent advances in the human physiology of inhibin secretion.

Authors:  D M de Kretser; D M Robertson; G P Risbridger
Journal:  J Endocrinol Invest       Date:  1990 Jul-Aug       Impact factor: 4.256

2.  Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia.

Authors:  Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 3.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

4.  Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass.

Authors:  Se-Jin Lee
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2010

5.  Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis.

Authors:  Xiangwei Gao; Saisai Wei; Kairan Lai; Jinghao Sheng; Jinfeng Su; Junqiao Zhu; Haojie Dong; Hu Hu; Zhengping Xu
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

6.  Follistatin has characteristics of a primary response gene in porcine granulosa cells.

Authors:  C E Lindsell; V Misra; B D Murphy
Journal:  Endocrine       Date:  1995-08       Impact factor: 3.633

7.  FOXL2 and BMP2 act cooperatively to regulate follistatin gene expression during ovarian development.

Authors:  Kenichi Kashimada; Emanuele Pelosi; Huijun Chen; David Schlessinger; Dagmar Wilhelm; Peter Koopman
Journal:  Endocrinology       Date:  2010-11-17       Impact factor: 4.736

Review 8.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

9.  FoxL2 and Smad3 coordinately regulate follistatin gene transcription.

Authors:  Amy L Blount; Karsten Schmidt; Nicholas J Justice; Wylie W Vale; Wolfgang H Fischer; Louise M Bilezikjian
Journal:  J Biol Chem       Date:  2008-12-23       Impact factor: 5.157

Review 10.  Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.

Authors:  Louise R Rodino-Klapac; Amanda M Haidet; Janaiah Kota; Chalonda Handy; Brian K Kaspar; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.